A novel syphilis Treponema pallidum lipoprotein peptide antigen diagnostic assay using red cell kodecytes in routine blood centre column agglutination testing platforms.
Treponema pallidum
blood safety
infectious disease
novel diagnostic assay
syphilis resurgence
Journal
Vox sanguinis
ISSN: 1423-0410
Titre abrégé: Vox Sang
Pays: England
ID NLM: 0413606
Informations de publication
Date de publication:
30 Jun 2024
30 Jun 2024
Historique:
revised:
16
03
2024
received:
22
12
2023
accepted:
18
03
2024
medline:
1
7
2024
pubmed:
1
7
2024
entrez:
1
7
2024
Statut:
aheadofprint
Résumé
The detection of treponemal antibodies, which are used to make a diagnosis of syphilis, is important both for diagnostic purposes and as a mandatory blood donor test in most countries. We evaluated the feasibility of using Kode Technology to make syphilis peptide red cell kodecytes for use in column agglutination serologic platforms. Candidate Kode Technology function-spacer-lipid (FSL) constructs were made for the Treponema pallidum lipoprotein (TmpA) of T. pallidum, using the peptide and FSL selection algorithms, and then used to make kodecytes. Developmental kodecytes were evaluated against a large range of syphilis antibody reactive and non-reactive samples in column agglutination platforms and compared against established methodologies. Overall, 150 reactive and 2072 non-reactive Syphicheck assay (a modified T. pallidum particle agglutination) blood donor samples were used to evaluate the agreement rate of the developed kodecyte assay. From three FSL-peptide candidate constructs, one was found to be the most suitable for diagnostics. Of 150 Syphicheck assay reactive samples, 146 were TmpA-kodecyte reactive (97.3% agreement), compared with 58.0% with the rapid plasmin reagin (RPR) assay for the same samples. Against the 2072 expected syphilis non-reactive samples the agreement rate for TmpA-kodecytes was 98.8%. TmpA-kodecytes are viable for use as cost-effective serologic reagent red cells for the detection of treponemal antibodies to diagnose syphilis with a high level of specificity in blood centres. This kodecyte methodology also potentially allows for introduction of the reverse-algorithm testing into low-volume laboratories, by utilizing existing transfusion laboratory infrastructure.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
The detection of treponemal antibodies, which are used to make a diagnosis of syphilis, is important both for diagnostic purposes and as a mandatory blood donor test in most countries. We evaluated the feasibility of using Kode Technology to make syphilis peptide red cell kodecytes for use in column agglutination serologic platforms.
MATERIALS AND METHODS
METHODS
Candidate Kode Technology function-spacer-lipid (FSL) constructs were made for the Treponema pallidum lipoprotein (TmpA) of T. pallidum, using the peptide and FSL selection algorithms, and then used to make kodecytes. Developmental kodecytes were evaluated against a large range of syphilis antibody reactive and non-reactive samples in column agglutination platforms and compared against established methodologies. Overall, 150 reactive and 2072 non-reactive Syphicheck assay (a modified T. pallidum particle agglutination) blood donor samples were used to evaluate the agreement rate of the developed kodecyte assay.
RESULTS
RESULTS
From three FSL-peptide candidate constructs, one was found to be the most suitable for diagnostics. Of 150 Syphicheck assay reactive samples, 146 were TmpA-kodecyte reactive (97.3% agreement), compared with 58.0% with the rapid plasmin reagin (RPR) assay for the same samples. Against the 2072 expected syphilis non-reactive samples the agreement rate for TmpA-kodecytes was 98.8%.
CONCLUSION
CONCLUSIONS
TmpA-kodecytes are viable for use as cost-effective serologic reagent red cells for the detection of treponemal antibodies to diagnose syphilis with a high level of specificity in blood centres. This kodecyte methodology also potentially allows for introduction of the reverse-algorithm testing into low-volume laboratories, by utilizing existing transfusion laboratory infrastructure.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Vox Sanguinis published by John Wiley & Sons Ltd on behalf of International Society of Blood Transfusion.
Références
Ghanem KG, Ram S, Rice PA. The modern epidemic of syphilis. N Engl J Med. 2020;382:845–854.
Perkins HA, Busch MP. Transfusion‐associated infections: 50 years of relentless challenges and remarkable progress. Transfusion. 2010;50:2080–2099.
Conti G, Notari EP, Dodd RY, Kessler D, Custer B, Reik R, et al. U.S. transfusion‐transmissible infections monitoring system (TTIMS). Syphilis seroprevalence and incidence in US blood donors from 2020 to 2022. Transfusion. 2024;64:325–333.
D'aes T, Van de Sande D, De Buck E, Zachée P, Compernolle V, Vandekerckhove P. Does cold storage of blood before transfusion prevent the transmission of syphilis? A systematic review and meta‐analysis. Vox Sang. 2024;119:219–231.
Kaur G, Kaur P. Syphilis testing in blood donors: an update. Blood Transfus. 2015;13:197.
Borg SA, Tenneti N, Lee A, Drewett GP, Ivan M, Giles ML. The reemergence of syphilis among females of reproductive age and congenital syphilis in Victoria, Australia, 2010 to 2020: a public health priority. Sex Transm Dis. 2023;50:479–484.
Kojima N, Klausner JD. An update on the global epidemiology of syphilis. Curr Epidemiol Rep. 2018;5:24–38.
Kubanov A, Runina A, Deryabin D. Novel Treponema pallidum recombinant antigens for syphilis diagnostics: current status and future prospects. Biomed Res Int. 2017;2017:1436080.
Park IU, Tran A, Pereira L, Fakile Y. Sensitivity and specificity of treponemal‐specific tests for the diagnosis of syphilis. Clin Infect Dis. 2020;71:S13–S20.
Binnicker MJ, Jespersen DJ, Rollins LO. Treponema‐specific tests for serodiagnosis of syphilis: comparative evaluation of seven assays. J Clin Microbiol. 2011;49:1313–1317.
Ortiz DA, Shukla MR, Loeffelholz MJ. The traditional or reverse algorithm for diagnosis of syphilis: pros and cons. Clin Infect Dis. 2020;71:S43–S51.
Rhoads DD, Genzen JR, Bashleben CP, Faix JD, Ansari MQ. Prevalence of traditional and reverse‐algorithm syphilis screening in laboratory practice: a survey of participants in the College of American Pathologists Syphilis Serology Proficiency Testing Program. Arch Pathol Lab Med. 2017;141:93–97.
Henry SM, Tuzikov AB, Bovin NV. Kode technology illustrated technical manual. 1st ed. Kode Biotech. 2023 Available from: https://hdl.handle.net/2292/62953. Last accessed 10 Nov 2023.
Nagappan R. Kode technology peptide‐based kodecyte diagnostics using spirochetes and SARS CoV‐2 as models [PhD Thesis]. Auckland University of Technology. 2021 Available from: https://hdl.handle.net/10292/14809. Last accessed 10 Nov 2023.
Nagappan R, Flegel WA, Srivastava K, Williams EC, Ryzhov I, Tuzikov A, et al. COVID‐19 antibody screening with SARS‐CoV‐2 red cell kodecytes using routine serologic diagnostic platforms. Transfusion. 2021;61:1171–1180.
Weinstock C, Flegel WA, Srivastava K, Kaiser S, Schrezenmeier H, Tsamadou C, et al. Erytra blood group analyser and Kode technology testing of SARS‐CoV‐2 antibodies among convalescent patients and vaccinated individuals. Eur J Hematol. 2022;3:72–79.
Srivastava K, West KA, De Giorgi V, Holbrook MR, Bovin NB, Henry SM, et al. COVID‐19 antibody detection and assay performance using red cell agglutination. Microbiol Spectr. 2021;9:e0083021.
Bristow CC, Klausner JD, Tran A. Clinical test performance of a rapid point‐of‐care syphilis treponemal antibody test: a systematic review and meta‐analysis. Clin Infect Dis. 2020;71:S52–S57.
Henry S, Williams E, Barr K, Korchagina E, Tuzikov A, Ilyushina N, et al. Rapid one‐step biotinylation of biological and non‐biological surfaces. Sci Rep. 2018;8:2845.
US Preventive Services Task Force. Screening for syphilis infection in nonpregnant adolescents and adults: US preventive services task force reaffirmation recommendation statement. JAMA. 2022;328:1243–1249.
Syphicheck‐WB. Rapid test for syphilis (modified TPHA). Available from: https://www.tulipgroup.com/PDFs/Rapid_Tests/IFU/SYPHICHECK‐WB‐(Device)‐IFU.pdf. Last accessed 10 Nov 2023.
Henry SM, Flegel WA, Weinstock C. Continuous population surveillance of COVID‐19 immunity can be provided by blood services at low cost using routine laboratory infrastructure. Blood Transfus. 2022;6:525–526.
Peeling RW, Holmes KK, Mabey D, Ronald A. Rapid tests for sexually transmitted infections (STIs): the way forward. Sex Transm Infect. 2006;82:v1–v6.
Waters A, Butler D, Coyne D, Williams P, O'Flaherty N, Hervig T. Putting blood donors at the heart of infectious disease surveillance. Transfusion. 2023;63:234A.